Abbott Laboratories
ABT
$101.95
-1.36%
Abbott Laboratories is a diversified healthcare company that develops and sells medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals, operating across more than 160 countries. As a global leader in medical devices and diagnostics, Abbott holds strong positions in areas like continuous glucose monitoring (FreeStyle Libre), cardiovascular devices, and point-of-care testing, with roughly 60% of sales derived outside the U.S. The current investor narrative centers on the company's growth recovery in core segments, particularly Medical Devices and Diagnostics, following a period of COVID-related volatility, while also weighing the impact of a recent guidance cut for 2026 that has created near-term uncertainty. Abbott's strategic moves, including the acquisition of Exact Sciences, are seen as catalysts for long-term growth, but the stock's underperformance relative to the market over the past year has sparked debate about whether this is a value opportunity or a sign of structural challenges.…
ABT
Abbott Laboratories
$101.95
Related headlines
Investment Opinion: Should I buy ABT Today?
Based on the analysis, ABT is rated a Buy. The thesis is that Abbott's diversified healthcare portfolio, strong revenue growth, and attractive forward valuation provide a favorable risk/reward. The analyst consensus of 'Buy' with an average target of $120.2 supports this view, implying 11% upside.
Sign up to view all
ABT 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Abbott's solid revenue growth and attractive forward valuation support a positive outlook, but the recent guidance cut and competitive pressures introduce uncertainty. The stock appears to offer a reasonable risk/reward, with the base case pointing to modest upside. If Abbott can deliver on its growth promises and maintain margins, the stock could re-rate higher. However, any further negative surprises could undermine the thesis. The AI stance would be upgraded to high confidence if the company raises guidance or if the stock drops to below $100, providing a better entry point.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $120.21 and implied upside of +17.9% versus the current price.
Average Target
$120.21
0 analysts
Implied Upside
+17.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $135
Analyst target range
The target price range spans from a low of $103.00 to a high of $135.00, representing a spread of $32.00, which indicates moderate uncertainty about the stock's future performance. The low target of $103.00 is slightly below the current price, suggesting that some analysts see limited downside but also limited upside, possibly reflecting concerns about the guidance cut and competitive pressures. The high target of $135.00 implies an upside of 24.6% from the current price, which would require strong execution on growth initiatives and margin recovery. The recent institutional ratings show no downgrades, with all actions being reaffirmations of Buy or Overweight, indicating that analyst sentiment remains stable and positive. The relatively wide range between low and high targets suggests that while the consensus is bullish, there is meaningful divergence in expectations regarding the pace of Abbott's recovery and its ability to achieve its long-term growth targets.
Bulls vs Bears: ABT Investment Factors
Abbott presents a mixed picture: strong revenue growth and a reasonable forward valuation are offset by a recent guidance cut and significant underperformance versus the market. The bull case rests on the company's ability to execute its growth strategy, particularly in Medical Devices, and achieve the earnings recovery implied by the forward PE. The bear case centers on whether the guidance cut signals deeper structural issues and whether competitive pressures will erode margins. Currently, the evidence slightly favors the bulls given the analyst consensus and attractive forward multiple, but the key tension is whether the company can deliver the expected earnings growth to justify the valuation. If Abbott meets or beats its revised guidance, the stock could re-rate higher; if not, it may continue to lag.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 7.8% YoY to $11.164B, with Medical Devices up strongly to $5.539B. This demonstrates robust demand across core segments, underpinning the growth thesis.
- Attractive Forward Valuation: Forward PE of 17.86x is well below trailing PE of 33.5x, implying significant expected earnings growth. This suggests the market is pricing in a recovery, making the stock look reasonably valued on forward earnings.
- Analyst Consensus Buy: With 25 analysts, the consensus is 'Buy' and the average target price is $120.2, implying ~11% upside from the current $108.33. No recent downgrades, with all actions being reaffirmations, indicates stable positive sentiment.
- Solid Profitability Metrics: Gross margin is 55.5% and operating margin is 18.2%, reflecting efficient operations. Net margin of 14.7% and ROE of 12.5% show the company is generating healthy returns.
Bearish
- Recent Guidance Cut: Abbott cut its 2026 profit outlook, overshadowing an earnings beat. This has created near-term uncertainty and contributed to the stock's 18.4% decline over the past year, signaling potential headwinds.
- Underperformance vs Market: Over the past year, ABT fell 18.4% while the S&P 500 rose 18.65%, a relative underperformance of 37%. This suggests the market is skeptical about the company's growth prospects.
- High Trailing PE: Trailing PE of 33.5x is elevated, reflecting lower current earnings. If earnings growth disappoints, the stock could face de-rating, as the current multiple may not be justified.
- Dividend Sustainability Concerns: Payout ratio of 63.1% is relatively high, leaving limited room for dividend growth if earnings falter. While the dividend yield is 1.88%, the high payout could constrain future increases.
ABT Technical Analysis
Abbott's stock is in a clear recovery phase after a significant downtrend. Over the past year, the stock has declined 18.4%, but it has rebounded strongly from its 52-week low of $81.97, currently trading at $108.33, which represents 78.8% of the 52-week range (from low to high). This positioning suggests the stock is recovering from oversold conditions but remains well below its 52-week high of $137.49, indicating that the prior bearish trend has not been fully reversed. The stock's beta of 0.581 indicates it is significantly less volatile than the broader market, which may appeal to risk-averse investors but also implies less upside participation in market rallies.
Beta
0.59
0.59x market volatility
Max Drawdown
-39.6%
Largest decline past year
52-Week Range
$82-$137
Price range past year
Annual Return
-23.1%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -8.1% | -1.1% |
| 3m | +15.6% | +3.0% |
| 6m | -5.6% | +15.4% |
| 1y | -23.1% | +16.2% |
| ytd | -17.9% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Abbott's revenue trajectory is showing solid growth, with the most recent quarter (Q1 2026) reporting revenue of $11.164 billion, up 7.8% year-over-year. This growth is consistent with the prior quarters, as Q4 2025 revenue was $11.459 billion, Q3 2025 was $11.369 billion, and Q2 2025 was $11.142 billion, indicating a stable growth rate in the mid-single to high-single digits. The growth is being driven by strong performance in Medical Devices (revenue of $5.539 billion) and Diagnostic Products ($6.2 billion), which together account for the majority of sales, while Nutritional Products ($2.017 billion) and Established Pharmaceuticals ($1.426 billion) provide diversification. The company's ability to sustain this growth is critical, as it underpins the investment thesis of a diversified healthcare leader.
Quarterly Revenue
$11.2B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
56.3%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 33.5x, while the forward PE is 17.86x, implying that the market expects significant earnings growth in the coming year. This wide gap between trailing and forward PE suggests that the market is pricing in a substantial recovery in profitability, likely driven by margin expansion and continued revenue growth. The forward PE of 17.86x is notably lower than the trailing multiple, which could indicate that the stock is undervalued relative to its expected earnings power, or it may reflect skepticism about the sustainability of current earnings levels.
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a moderate debt-to-equity ratio of 0.29, which is manageable, but the company's net margin of 14.7% could be pressured by rising costs. The high payout ratio of 63.1% limits financial flexibility, and any earnings shortfall could strain dividend growth. Free cash flow of $7.378B TTM provides a cushion, but the company's reliance on continued revenue growth to justify its forward PE is a key risk. If growth decelerates below the mid-single digits, the stock could face de-rating.